Pharmacogenomics Market By Type (Products {Reagents & kits, Instruments, Software & bioinformatics tools}, Services {Genotyping services, Sequencing services, Data analysis & interpretation, Clinical decision support services, Custom testing services}), By Application (Drug discovery & development, Clinical applications, Adverse drug reaction (ADR) prevention, Personalized medicine initiatives), By Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Microarray technology, Mass spectrometry, In situ hybridization, Others), By Gene Type (Cytochrome P450 enzymes, Thiopurine methyltransferase, N-acetyltransferase, UDP-glucuronosyltransferases, VKORC1 gene, HLA variants, Others), and By End User (Hospitals & clinics, Academic & research institutions, Pharmaceutical & biotechnology companies, Diagnostic laboratories, Contract research organizations, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

What trends will shape Pharmacogenomics Market in the coming years?

The Pharmacogenomics Market accounted for USD 8.01 Billion in 2024 and USD 8.67 Billion in 2025 is expected to reach USD 19.08 Billion by 2035, growing at a CAGR of around 8.21% between 2025 and 2035. The pharmacogenomics market refers to the study and implementation of how the genetic composition of an individual responds to drugs. It integrates both pharmacology and genomics to establish individualised medicine with the aim of enhancing the efficacy of the drug as well as minimising the side effects. This market comprises diagnostic testing, drug development, and individualised treatment strategies. It is being fuelled by increasing interest in the field of precision medicine, increased incidence of chronic diseases, and advances in the field of genetic research. The main participants are biotech companies, pharmaceutical companies, and developers of diagnostics. The market has great potential to push the conventional one-size-fits-all healthcare strategies.

What do industry experts say about the Pharmacogenomics market trends?

"Pharmacogenomics allows us to move beyond one-size-fits-all prescribing and instead tailor therapies based on a patient’s genetic profile, improving efficacy and safety."

• Dr. Julie A. Johnson, Dean and Distinguished Professor, University of Florida College of Pharmacy

"The integration of pharmacogenomics into clinical care is transforming drug development and personalized medicine by reducing adverse drug reactions and optimizing treatment outcomes."

• Dr. Russ Altman, Professor of Bioengineering, Genetics, and Medicine, Stanford University

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the Pharmacogenomics market?

What role does genetic testing play in reducing adverse reactions?

Genetic testing is essential for reducing the likelihood of negative reactions to drugs because it allows for the creation of treatment plans that are suited to an individual and their genes. For example, healthcare professionals can make informed assumptions about how a patient will react to specific medicines if they have the means to test for other genetic changes that impact the metabolism of drugs, such as the CYP450 enzyme family. The U.S. National Institutes of Health (NIH) states that pharmacogenomic testing is beneficial because it makes it possible to prevent damaging side effects by changing either the drug or its dose on the basis of genetic profiles.

The FDA has also integrated genetic information into the drug labels of more than 250 drugs to highlight the significance of genetics in the safe use of drugs. Through research, it has been shown that adverse drug reactions are responsible for the death of more than 100,000 people every year in the U.S., a large portion of which could be avoided with the use of genetic testing. Pharmacogenomics has a positive effect on reducing healthcare costs incurred through hospitalisations from adverse reactions, through amplifying treatment efficacy in addition to patient safety.

Why is rising chronic disease prevalence boosting pharmacogenomics demand globally?

The increasing incidence of chronic conditions such as heart disease, diabetes, cancer, and lung diseases significantly drives the need for pharmacogenomics globally. The World Health Organisation (WHO) estimates that deaths due to non-communicable diseases (NCDs) reach approximately 40 million, which is nearly 74% of global deaths. Such diseases typically need complicated treatments in which different patients show different responses to the same drugs, often with pharmacogenomics.

By looking at the genes, pharmacogenomics allows personalised medicine and can tell how effectively the drugs will work, as it helps in improving treatment and reducing the side effects, which is a huge help. As a result of the need to improve treatment effectiveness and to fight the increasing cost of treating chronic diseases, pharmacogenomics represents an appropriate and economical intervention to chronic disease management. To fight chronic diseases effectively, educational institutions and health agencies advocate for pharmacogenomics.

How do high testing costs limit accessibility in rural regions?

The cost of testing is the single biggest roadblock to pharmacogenomics (PGx) in rural settings. Rural hospitals have no means of conducting genetic testing, but the low income of the largely uninsured patient base makes funding such tests out of pocket impossible. The cost of genetic testing is several hundred, if not several thousand, dollars, much of which the sufferers in rural areas, where there is poverty compared to urban areas, will not be able to afford.

The CDC points out that because there are not enough testing laboratories in the local area, samples have to be shipped to far-off places, which creates additional costs and also some delay. The lack of funding and the logistics together form a strong deterrent to the use of pharmacogenomics in rural healthcare, leaving fewer funds to tailor treatment medication and possibly resulting in poorer treatment results. Therefore, high costs of testing limit the advantages of precision medicine to only the richer and people in urban settings; as already stated, this further widens the healthcare gap.

How can AI integration improve genomic data interpretation and delivery?

AI has established itself in the healthcare industry by integrating its technologies into pharmacogenomics, just like every other area. AI is now able to interpret pharmacogenomic data with more accuracy and in less time. The advanced machine learning algorithms and AI technologies have the ability to analyse vast genomic data sets in an incredibly short time and pick out the genetic variants that affect drug response. The integration of AI technologies in pharmacogenomics has also reduced the interpretation time of sequencing data from weeks to days, as reported by the National Institute of Health. This opens up opportunities to leverage this data for personalised treatment in a much shorter time frame.

The FDA, in their recent report, showed concern that AI technologies can help to build better predictive models that are able to lower untoward drug effects through optimised drug prescriptions based on genetic make-up. Renowned institutions such as MIT are of the view that AI provides a sharper understanding of a patient’s drug metabolism and disease pathways by integrating multi-omics data, which helps in devising drug regimens that are safer and more effective. This supports the shift towards precision medicine. As the amount of genomic data increases, healthcare institutions will greatly benefit from AI-powered systems that convert data into pharmacogenomic knowledge, improving patient care while cutting down the costs of treatment.

Why is increasing investment in biotechnology accelerating innovative solution development?

Research on the genetic components of drug response is being supported by increased biotechnology spending, which is propelling innovation in the pharmacogenomics market. While India's Department of Biotechnology is investing in the GenomeIndia project, which aims to catalogue the nation's genetic variation, the U.S. National Institutes of Health (NIH) is funding precision medicine research to the tune of several hundred million dollars. Such initiatives have resulted in significant research progress and numerous patent filings, signalling the availability of new pharmacogenomic inventions.

The support improves the possibilities of creating therapies that are more effective and safer to administer. Investments of this nature, as the World Health Organisation highlights, lessen the frequency of harmful drug reactions by refining the fit of drugs to the genetic machinery of each patient. Increasing biotechnology investments fosters the transition of innovative pharmacogenomic technologies from the laboratory to clinical practice.

What are the key market segments in the Pharmacogenomics industry?

Based on the type, the Pharmacogenomics Market is classified into Products and Services. Among all market drivers, pharmacogenomic testing services stand out as the most significant one, particularly in the pharmacogenomics market. The demand for personalised medicine is increasing, and people want treatments for drugs that are effective for their genomes. Testing works towards rendering drug treatments effective in terms of drugs prescribed to an individual. This increases the effectiveness of a drug and reduces the risk of contracting any additional drug problems.

The services are also increasingly adopted due to the rising prevalence of genomic technologies and the increasing awareness of pharmacogenomic testing services among the providers and patients. In addition, the prevalence of chronic diseases and cancer increases the need for pharmacogenomic testing and makes it the most important segment of this market.

Based on the application, the Pharmacogenomics Market is classified into Drug discovery & development, Clinical applications, Adverse drug reaction (ADR) prevention, Personalized medicine initiatives. The pharmacogenomics market is driven by the initiatives or programmes targeted at personalised medicine. As an application, it is highly impactful because it seeks to optimise drug therapies by taking into account the patient's DNA, leading to improved treatment outcomes and fewer side effects.

The impact of personalised medicine is changing the old ways of treatment, driven by its focus on precision healthcare. Additional funding from healthcare providers and pharma companies to adopt genetic information in everyday healthcare increases the influence of this segment. In addition, patient knowledge of medicines, coupled with regulatory aid, enables this segment to lead the pharmacogenomics arena.

Which regions are leading the Pharmacogenomics market, and why?

The North American pharmacogenomics market has been dominated due to developed healthcare infrastructure, has a well-established pharmaceutical and biotech industry, and has embraced the concept of precision medicine early. The area has enjoyed massive government and corporate investment in genome research, in addition to positive regulatory environments that favour the development of new drugs. The demand is also caused by high awareness among healthcare professionals and patients of the benefits of personalised medicine.

In the U.S. specifically, there are numerous ongoing clinical trials and academic partnerships in the area of pharmacogenomics. Furthermore, the availability of genetic testing and electronic health records is widespread, and pharmacogenomic data is being integrated into clinical practice, further reinforcing the leadership of the region in the market. The rising number of chronic illnesses and the escalating amount of health care spending are contributing to the rising incidence of individualised therapies in North America. All this makes the region stay at the leading edge of pharmacogenomics innovation and adoption.

A cocktail of factors, such as a large and genetically diverse population and growing investments in the healthcare infrastructure, are dominating the Asia Pacific pharmacogenomics market. Other countries such as China, Japan, South Korea and India are developing an interest in precision medicine and genomics research and are backed by government activities and partnerships between academia and pharmaceutical corporations. Adoption is being accelerated by increased awareness of personalised medicine and the decreasing price of genetic testing. Moreover, chronic diseases are prevalent in the area, which requires more effective, person-specific treatment methods.

Skilled professionals and innovations in bioinformatics also help to facilitate the rapid growth of the market in the region. The market landscape is also reinforced by increasing pharmaceutical research and development and the growing network of clinical trials. Overall, these changes establish Asia Pacific as the leading player in the pharmacogenomics market worldwide.

What does the competitive landscape of the Pharmacogenomics market look like?

Genetic insights are increasingly becoming the focus of the pharmacogenomics market as companies attempt to promote personalised medicine. Major competitors, such as Thermo Fisher Scientific, Illumina, Roche, QIAGEN, and Bio-Rad Laboratories, innovate with genomic analysis technology and expand service offerings in their portfolios. Thermo Fisher and Illumina keep pushing the limit on sequencing platforms to make it possible to predict the drug response more efficiently. Roche and QIAGEN are interested in applying pharmacogenomic data to clinical decision-making, and QIAGEN has recently improved its digital knowledge capabilities.

Bio-Rad continues to be a force even though proprietary DNA analysis technologies have had a few legal challenges. Further, other companies (Agilent Technologies, OneOme, etc.) are increasing their international footprint and providing new testing solutions to enhance the safety and efficacy of treatment. Overall, the field is characterised by the fast development of technologies and growing partnerships aimed at introducing pharmacogenomics into everyday clinical use.

Pharmacogenomics Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the Pharmacogenomics industry?

• In July 2025, PGxAI published benchmarking results comparing LLMs for generating guideline-based pharmacogenomic recommendations. Their domain-adapted model achieved an LLM Score of 0.92, significantly outperforming general-purpose models in both accuracy and speed. This laid the foundation for safer AI-driven clinical decision support in pharmacogenomics.
• In June 2025, PGxAI launched Betelgeuse, an AI model for real-time clinical outcome analysis and adaptive treatment recommendations. It complemented their earlier model, Deneb, by integrating multi-omics data, patient history, and pharmacogenetic insights. The model aimed to reduce adverse events by around 30%, marking a move toward dynamic therapeutic adjustment in precision medicine.

Report Coverage:

By Type

• Products
  • Reagents & kits
  • Instruments
  • Software & bioinformatics tools
• Services
  • Genotyping services
  • Sequencing services
  • Data analysis & interpretation
  • Clinical decision support services
  • Custom testing services

By Application

• Drug discovery & development
• Clinical applications
• Adverse drug reaction (ADR) prevention
• Personalized medicine initiatives

By Technology

• Polymerase Chain Reaction (PCR)
• Next-Generation Sequencing (NGS)
• Microarray technology
• Mass spectrometry
• In situ hybridization
• Others

By Gene Type

• Cytochrome P450 enzymes
• Thiopurine methyltransferase
• N-acetyltransferase
• UDP-glucuronosyltransferases
• VKORC1 gene
• HLA variants
• Others

By End User

• Hospitals & clinics
• Academic & research institutions
• Pharmaceutical & biotechnology companies
• Diagnostic laboratories
• Contract research organizations
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Thermo Fisher Scientific
• Illumina
• F. Hoffmann-La Roche Ltd.
• QIAGEN N.V.
• Bio-Rad Laboratories
• Agilent Technologies
• Eurofins Scientific
• Becton, Dickinson and Company (BD)
• Myriad Genetics
• Admera Health
• Pathway Genomics
• OneOme LLC
• Dynamic DNA Laboratories
• Laboratory Corporation of America Holdings (LabCorp)
• Charles River Laboratories

Frequently Asked Questions (FAQs)